Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions

Area of Science:

• Dermatology
• Infectious Diseases
• Pharmacology

Background:

• Leprosy treatment involves short-course chemotherapy.
• Understanding treatment-related reactions is crucial for patient management.
• Paucibacillary (PB) and multibacillary (MB) leprosy require different therapeutic approaches.

Purpose of the Study:

• To systematically evaluate reactions during various short-course leprosy therapy regimens.
• To compare the incidence and severity of type 1 upgrading reactions in PB and MB leprosy patients.
• To assess the role of specific drugs, like clofazimine, in preventing or mitigating reactions.

Main Methods:

• Comparative study of different short-course chemotherapy regimens for PB and MB leprosy.
• Monitoring and documentation of type 1 upgrading reactions and Erythema Nodosum Leprosum (ENL).
• Analysis of reaction incidence and severity in relation to specific drug regimens and dosages.

Main Results:

• Type 1 reactions in PB leprosy were generally mild and short-lived, with incidence varying by rifampin regimen.
• In MB leprosy, type 1 reactions were more frequent and severe with regimens C and D compared to the MB-WHO regimen.
• Daily clofazimine (100 mg) in MB patients prevented type 1 reactions and reduced their severity, but did not prevent ENL.

Conclusions:

• Regimen choice significantly influences the occurrence and severity of leprosy reactions.
• Clofazimine demonstrates a protective effect against type 1 reactions in multibacillary leprosy.
• Further research is needed to understand the correlation between rifampin administration and reaction development.